Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention
- PMID: 39345160
- PMCID: PMC11440178
- DOI: 10.1093/europace/euae245
Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention
Abstract
Aims: The decisions about placing an ICD in a child are more difficult than in an adult due to longer expected lifespan and the complication risk. Young patients gain the most years from ICDs, despite higher risk of device-related complications. The secondary prevention ICD indication is clear, and device is implanted regardless of potential complications. For primary prevention, risk of sudden cardiac death and complications need to be evaluated. We aimed to compare outcomes for primary and secondary prevention ICDs.
Methods and results: Retrospective nationwide cohort study including paediatric patients identified from the Danish ICD registry with ICD implanted at an age ≤ 15 from 1982-21. Demographics, complications (composite of device-related infections or lead-failure requiring re-operation, mortality because of arrhythmia, or unknown cause), and mortality were retrieved from medical charts. Endpoint was appropriate therapy (shock or anti-tachycardia pacing for ventricular tachycardia or fibrillation). Of 72 receiving an ICD, the majority had channelopathies (n = 34) or structural heart diseases (n = 28). ICDs were implanted in 23 patients for primary prevention and 49 for secondary prevention, at median ages of 13.8 and 11.6 years (P-value 0.01), respectively. Median follow-up was 9.0 (interquartile ranges: 4.7-13.5) years. The 10-year cumulative incidence of first appropriate therapy was 70%, with complication and inappropriate therapy rates at 41% and 15%, respectively. No difference was observed between prevention groups for all outcomes. Six patients died during follow-up.
Conclusion: In children, two-thirds are secondary prevention ICDs. Children have higher appropriate therapy and complication rates than adults, while the inappropriate therapy rate was low.
Keywords: Appropriate therapy; Congenital heart disease; Implantable cardioverter defibrillator; Paediatric cardiology; Sudden cardiac death.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Conflict of interest: C.J. receives lecturing fees from Abbott and Biosense Webster. P.S.B. receives educational grant from Abbott, fellowship/scholarship grant from Boston Scientific, and an external research support (ERP-2021-12822) from Medtronic. LS. is chief medical officer and divisional vice president at Medical Affairs, Abbott Structural Heart. J.C.N. received institutional research grants from the Novo Nordisk Foundation and the Danish Heart Foundation outside this work. The remaining authors have no conflicts of interest to declare.
Figures




Similar articles
-
Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.BMC Cardiovasc Disord. 2019 Oct 21;19(1):230. doi: 10.1186/s12872-019-1218-9. BMC Cardiovasc Disord. 2019. PMID: 31638918 Free PMC article.
-
Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.J Am Heart Assoc. 2017 Aug 19;6(8):e006220. doi: 10.1161/JAHA.117.006220. J Am Heart Assoc. 2017. PMID: 28862957 Free PMC article.
-
Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.BMC Cardiovasc Disord. 2021 Feb 19;21(1):106. doi: 10.1186/s12872-021-01910-0. BMC Cardiovasc Disord. 2021. PMID: 33607967 Free PMC article.
-
Ventricular arrhythmias and sudden cardiac death in adults with congenital heart disease.Heart. 2016 Nov 1;102(21):1703-1709. doi: 10.1136/heartjnl-2015-309069. Epub 2016 Jun 1. Heart. 2016. PMID: 27250216 Review.
-
Systematic Review and Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Therapy in Patients With Chagas Heart Disease.JACC Clin Electrophysiol. 2019 Oct;5(10):1213-1223. doi: 10.1016/j.jacep.2019.07.003. Epub 2019 Aug 28. JACC Clin Electrophysiol. 2019. PMID: 31648747
Cited by
-
Sudden cardiac death in congenital heart disease-a narrative review and update.Front Cardiovasc Med. 2025 Apr 30;12:1539958. doi: 10.3389/fcvm.2025.1539958. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40371062 Free PMC article. Review.
-
The extravascular implantable defibrillator: a novel opportunity for the paediatric population.Europace. 2025 Jul 1;27(7):euaf128. doi: 10.1093/europace/euaf128. Europace. 2025. PMID: 40567174 Free PMC article. No abstract available.
-
Implantable cardioverter defibrillators in paediatric patients: yet another example of healthcare divergence?Europace. 2024 Aug 30;26(9):euae230. doi: 10.1093/europace/euae230. Europace. 2024. PMID: 39228363 Free PMC article. No abstract available.
-
Minimally Invasive Implantation of an Extravascular Implantable Cardioverter-Defibrillator Device in a 2 Year Old.Ann Thorac Surg Short Rep. 2024 Dec 16;3(2):469-472. doi: 10.1016/j.atssr.2024.12.001. eCollection 2025 Jun. Ann Thorac Surg Short Rep. 2024. PMID: 40525144 Free PMC article.
References
-
- Baskar S, Bao H, Minges KE, Spar DS, Czosek RJ. Characteristics and outcomes of pediatric patients who undergo placement of implantable cardioverter defibrillators: insights from the national cardiovascular data registry. Circ Arrhythm Electrophysiol 2018;11:e006542. - PubMed
-
- Czosek RJ, Meganathan K, Anderson JB, Knilans TK, Marino BS, Heaton PC. Cardiac rhythm devices in the pediatric population: utilization and complications. Heart Rhythm 2012;9:199–208. - PubMed
-
- Walsh EP. Practical aspects of implantable defibrillator therapy in patients with congenital heart disease. Pacing Clin Electrophysiol 2008;31 Suppl 1:S38–40. - PubMed
-
- Writing Committee Members; Silka MJ, Shah MJ, Silva JNA, Balaji S, Beach CMet al. . 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: executive summary. Heart Rhythm 2021;18:1925–50. - PubMed
-
- Jordan CP, Freedenberg V, Wang Y, Curtis JP, Gleva MJ, Berul CI. Implant and clinical characteristics for pediatric and congenital heart patients in the national cardiovascular data registry implantable cardioverter defibrillator registry. Circ Arrhythm Electrophysiol 2014;7:1092–100. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical